<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32259519</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2941</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>229</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Chemistry and physics of lipids</Title>
          <ISOAbbreviation>Chem Phys Lipids</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Unique responses of Helicobacter pylori to exogenous hydrophobic compounds.</ArticleTitle>
        <Pagination>
          <StartPage>104908</StartPage>
          <MedlinePgn>104908</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chemphyslip.2020.104908</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0009-3084(20)30039-6</ELocationID>
        <Abstract>
          <AbstractText>Helicobacter pylori is a pathogen responsible for peptic ulcers and gastric cancers in human. One of the unique biological features of this bacterium is a membrane lipid composition significantly differed from that of typical Gram-negative bacteria. Due to its unique lipid composition, the responses of H. pylori to various exogenous lipophilic compounds significantly differ from the responses of typical Gram-negative bacteria to the same lipophilic compounds. For instance, some steroidal compounds are incorporated into the biomembranes of H. pylori through the intermediation of the myristoyl-phosphatidylethanolamine (PE). In addition, H. pylori shows high susceptibility to bacteriolytic action of lipids such as 3-carbonyl steroids, vitamin D, and indene compounds. These lipids are also considered to interact with myristoyl-PE of H. pylori membranes, and to ultimately confer the bactericidal action to this bacterium. In this study we summarize the lipids concerned with H. pylori and suggest the possibility of the development of chemotherapeutic medicines that act on the membrane lipid component of H. pylori.</AbstractText>
          <CopyrightInformation>Copyright Â© 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shimomura</LastName>
            <ForeName>Hirofumi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Big Bear Veterinary Hospital, 3-1-5, Oyama, Higashi-ku, Kumamoto-shi, Kumamoto, 861-8045, Japan. Electronic address: shimomura20090601@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wanibuchi</LastName>
            <ForeName>Kiyofumi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmaceutical Sciences, Yokohama University of Pharmacy, 601, Matano-cho, Totsuka-ku, Yokohama-shi, Kanagawa, 245-0066, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hosoda</LastName>
            <ForeName>Kouichi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Nikon Cell Innovation Co., Ltd., 2-4-10, Shinsuna, Koto-ku, Tokyo, 136-0075, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amgalanbaatar</LastName>
            <ForeName>Avarzed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, School of Bio-Medicine, Mongolian National University of Medical Sciences, 14210, Zoing street, Sukhbaatar District, Ulaanbaatar, 14210, Mongolia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masui</LastName>
            <ForeName>Hisashi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmaceutical Sciences, Yokohama University of Pharmacy, 601, Matano-cho, Totsuka-ku, Yokohama-shi, Kanagawa, 245-0066, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmaceutical Sciences, Yokohama University of Pharmacy, 601, Matano-cho, Totsuka-ku, Yokohama-shi, Kanagawa, 245-0066, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirai</LastName>
            <ForeName>Yoshikazu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Tamano Institute of Health and Human Services, 1-1-20, Chikko, Tamano-shi, Okayama, 760-0002, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Chem Phys Lipids</MedlineTA>
        <NlmUniqueID>0067206</NlmUniqueID>
        <ISSNLinking>0009-3084</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008563">Membrane Lipids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016480" MajorTopicYN="N">Helicobacter pylori</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057927" MajorTopicYN="N">Hydrophobic and Hydrophilic Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008563" MajorTopicYN="N">Membrane Lipids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cholesterol</Keyword>
        <Keyword MajorTopicYN="Y">Helicobacter pylori</Keyword>
        <Keyword MajorTopicYN="Y">Myristate</Keyword>
        <Keyword MajorTopicYN="Y">Phosphatidylethanolamine</Keyword>
        <Keyword MajorTopicYN="Y">Steroid</Keyword>
        <Keyword MajorTopicYN="Y">Vitamin D</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32259519</ArticleId>
        <ArticleId IdType="doi">10.1016/j.chemphyslip.2020.104908</ArticleId>
        <ArticleId IdType="pii">S0009-3084(20)30039-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
